Clinical Trial Update: A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study of a single oral dose of GSK189075 containing trace radioactivity in healthy male volunteers; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GSK189075 (GSK189075)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED